The earnings call presents a generally positive outlook for Zai Lab, with strong revenue growth and a clear path towards profitability. VYVGART shows significant promise in the Chinese market, supported by updated guidelines. However, there are challenges such as competitive pressures on ZEJULA and supply issues affecting XACDURO. The company's diversified pipeline and strategic use of AI and local expertise provide a solid foundation for future growth.

Company Guidance

During the second quarter of 2025, Zai Lab reaffirmed its full-year revenue guidance of USD 560 million to USD 590 million and announced its trajectory towards achieving profitability in the fourth quarter. The company emphasized strong commercial execution, particularly with VYVGART, which showed record levels of patient utilization and increasing treatment duration, positioning it for significant long-term growth in China. Zai Lab's regional business is poised for substantial growth with the expected approvals of KarXT in schizophrenia and TIVDAK in cervical cancer. The company is also advancing its global R&D pipeline, with ZL-1310 (DLL3 ADC) demonstrating promising results in small cell lung cancer. Furthermore, Zai Lab is exploring label expansion opportunities for VYVGART across multiple immunology indications and expects it could exceed $1 billion in peak sales. Overall, Zai Lab continues to leverage its scalable commercial model and strategic investments to drive long-term growth and value.

Strong Revenue Growth

Total revenue grew 9% year-over-year to $110 million in the second quarter, driven by higher sales of VYVGART and other products.

Profitability on Horizon

Zai Lab is on track to achieve profitability in the fourth quarter of 2025 on an adjusted basis, with operating loss reduced by 37%.

VYVGART Momentum

Strong commercial execution for VYVGART in gMG with record levels of patient utilization and new patient starts, supported by updated national MG guidelines in China.

Pipeline Advancements

Progress in the pipeline with promising data for ZL-1310 in small cell lung cancer and multiple upcoming regulatory submissions.

Zai Lab (ZLAB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZLAB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.25 / -	-0.42	―	―	―
Aug 07, 2025	2025 (Q2)	-0.36 / -0.37	-0.82	54.88% (+0.45)
May 08, 2025	2025 (Q1)	-0.55 / -0.45	-0.55	18.18% (+0.10)
Feb 27, 2025	2024 (Q4)	-0.65 / -0.80	-1.63	50.92% (+0.83)
Nov 12, 2024	2024 (Q3)	-0.78 / -0.42	-0.07	-500.00% (-0.35)
Aug 06, 2024	2024 (Q2)	-0.71 / -0.82	-1.25	34.40% (+0.43)
May 08, 2024	2024 (Q1)	-0.93 / -0.55	-0.51	-7.84% (-0.04)	―
Feb 27, 2024	2023 (Q4)	-0.86 / -1.63	-0.65	-150.77% (-0.98)
Nov 07, 2023	2023 (Q3)	-1.04 / -0.07	-1.68	95.83% (+1.61)	―
Aug 07, 2023	2023 (Q2)	-0.79 / -1.25	-1.44	13.19% (+0.19)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ZLAB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$38.72	$34.08	-11.98%
May 08, 2025	$28.36	$29.14	+2.75%
Feb 27, 2025	$35.07	$34.38	-1.97%
Nov 12, 2024	$31.09	$28.96	-6.85%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zai Lab (ZLAB) report earnings?

Zai Lab (ZLAB) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Zai Lab (ZLAB) earnings time?

Zai Lab (ZLAB) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ZLAB EPS forecast?

ZLAB EPS forecast for the fiscal quarter 2025 (Q3) is -0.25.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing